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Teaser(25 words) 
AI comes to lead optimization: medicinal chemistry in all disease areas can be accelerated by 
exploiting our pre-competitive knowledge in an unbiased way. 
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Abstract(100 words) 
 
It is both the best of times and the worst of times to be a medicinal chemist.  Massive amounts of 
data combined with machine learning / artificial intelligence (AI) tools to analyse it can increase 
our capabilities. However, drug discovery faces severe economic pressure and a high level of 
societal need against very challenging targets. We show how improving medicinal chemistry by 
better curating and exchanging knowledge can contribute to improving drug hunting in all disease 
areas. Securing intellectual property is a critical task for medicinal chemists, however it impedes the 
sharing of generic medicinal chemistry knowledge. Recent developments enable sharing 
knowledge both within and between organizations while securing intellectual property. Finally the 
effects of the structure of drug discovery's corporate ecosystem on knowledge sharing is explored. 
 
Critical Glossary 
 
Matched Molecular Pair Analysis (MMPA) a technique for chemical structure activity or 
 property analysis where single precise changes to molecule 
 structures are identified and the effect of the same change 
 (described as a transformation) is studied across multiple pairs 
 of molecules to identify transformations that are transferable 
 between chemical series[1] 
Quantitative Structure Activity  
Relationship models Mathematical models built from descriptors of individual  
 molecule structures that aim to predict biological or 
 physicochemical properties of new proposed molecules[2,3] 
Econometrics mathematical economics[4] 
Publication bias bias in research where the outcome of the research biases the 
 public disclosure, a particular problem in using public data sets 
 to infer knowledge[5,6] 
Hierarchy of evidence a ranking of different types of study when making decisions, 
 with the highest level being least prone to systematic bias and 
 the lowest level being anecdotes or expert opinion[7] 
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The goal of this paper is to show how it is possible to accelerate drug discovery by analyzing, 
systematizing and sharing medicinal chemistry knowledge in an unbiased and coherent way. This is 
at the core of AI approaches based on supervised learning. The fall in productivity of drug discovery 
is reviewed and the role medicinal chemistry has to play addressing this issue is highlighted. We 
discuss how the human aspects of working within a drug discovery team impact on the practice of 
medicinal chemistry and how using more evidence-driven approaches can counter-balance 
natural human cognitive biases. The central part of this work shows how application of modern 
approaches to systematizing knowledge in an unbiased way can both extract new knowledge and 
circumvent the confidentiality issues created by the need to generate intellectual property(IP). 
Finally, we discuss the corporate challenges and benefits to global drug discovery in sharing 
medicinal chemistry knowledge broadly between large Pharmaceutical companies and more 
widely with the academic, not-for-profit and biotech sectors. 
The Central Challenge for Chemists in Drug Discovery 
Drug discovery is facing severe economic stress against a background of increasing societal need. 
The output of global drug discovery has held surprisingly constant with a median of 16 NMEs 
launched per year between 1950 - 2014.  Taking a straightforward definition of productivity in drug 
discovery as the number of NCE's brought to market divided by cost, longitudinal analysis shows an 
average annual increase in cost of 8% per annum – christened "Erooms Law" [8]. A drop in 
productivity that few budgets in any industry can tolerate. Using 2016 prices: in 1950 a billion dollars 
would deliver over 30 drugs to market, today: less than one.  Against this background the repeated 
organizational "efficiency drives" in drug discovery have clearly failed to deliver the promised 
radical improvements in productivity. Even rigorous application of good decision making practice 
and focusing research resources as recently discussed by Pangalos et al[9] although useful are 
nowhere near returning us to the heights of 1950's productivity 
 Econometric analysis of the areas of cost in drug discovery challenges the traditional view 
that Phase III trials represent the highest cost section in the process. Accounting for attrition, portfolio 
modeling and the cost of capital, the true area for maximum process improvement is in the lead 
optimization phase, as it occurs relatively early in the research and development cycle, is long, 
expensive and has a significant attrition rate[4].  A recent analysis[10] of the contrast between the 
technological and organizational advances  made over the last 60 years makes the key point that 
accessing compounds active in a disease-relevant in vivo model remains the critical turning point in 
a drug discovery program from a scientific and investment perspective. The responsibility of the 
biologists in drug hunting teams is ensuring that the targets, assays and experimental models are 
aligned to the disease state. Here understanding the historic probability of success in different 
target classes may be of value[11], however the ingenuity of chemists has often overcome what 
were perceived as "undruggable" classes as demonstrated by recent progress in protein-protein 
interactions enabled by structural biology, fragment based lead generation and DNA encoded 
libraries[12]. There has been significant progress in this area using automated methods to identify 
better drug targets. The key roles of the chemists are to find and optimize compounds to the point 
where they can be dosed in vivo to the disease model and generate the critical data to select the 
right compound to take into the clinic. 
 Reducing the cost of lead optimization campaigns by accelerating them would allow more 
lead series to be studied per project and more biological approaches targeted per disease state. 
This has the potential to significantly increase the probability of developing new therapeutic 
approaches for an aging global population and address emerging threats from drug resistant 
pathogens.  
How can we accelerate Medicinal Chemistry? 
Accelerating lead optimization entails addressing the central technical challenge of medicinal 
chemistry, which is the need to optimize potency at the biological target while simultaneously 
maintaining bioavailability through the appropriate therapeutic route of administration and 
avoiding toxicity; a highly challenging multifactorial design problem.  Unsurprisingly, the design-
make-test-analyze cycle most commonly used as a cyclic prototyping process usually requires a 
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large number of cycles for success, with the chemists using experience, chemical knowledge and 
simple general rules for guidance. The challenge implicit in these approaches is the build up of 
mental models that may become rigid and a practitioner or team may become “stuck” in a 
chemical series unable to deliver compounds with adequate properties to use in vivo. 
 Medicinal chemistry has gathered huge amounts of in vitro testing data in the last three 
decades particularly addressing ADME and toxicology issues. The vast majority of this is held in data 
vaults that are in danger of becoming data tombs if the knowledge contained there cannot be 
exploited[13]. The key non-technical goal in medicinal chemistry is the requirement to generate 
intellectual property in order to generate a return on the investment in research. This constraint 
means inactive or compromised structures are usually not publicly disclosed to avoid weakening IP 
positions. This generates a very significant publication bias[5] of chemical matter as spectacularly 
shown by Kramer et al [14] analyzing the distribution of potency data in ChEMBL where the modal 
pKi is 8.5. No practicing medicinal chemist would expect “average” compounds to have 
nanomolar potency. This lack of balanced publications generates a conflict between the societal 
need to lower the cost of drug discovery by improving medicinal chemistry practice and the 
commercial imperative to secure patents.  
 Across all fields of science, the cycling between systematizing knowledge leading to 
experiments, analysis of the causes of relationships and the rationalization of exceptions has driven 
progress. Though all codification and classifications are partial and flawed they create a framework 
for exploration and dialogue. Although a map is not a full description of a territory, it may be 
sufficient for navigation. The exceptions to apparent “rules” are fertile locations for exploring the 
underlying drivers of phenomena. Historically, the Chemical Abstract Service, Beilstein, Gmelin and 
more recently the ChEMBL, PDB and CCDC databases have all made a significant difference to the 
progression of chemistry, although it is hard to quantify their exact value. 
 Systematization of medicinal chemistry has therefore three main benefits: 1) the immediate 
understanding of what effects a particular chemical modification is most likely to have on an 
ADMET property to solve problems in a drug hunting program, 2) to create a corpus of knowledge 
that enables trends and meta-rules to be extracted and finally, 3) to generate hypotheses to test 
mechanistic understanding. All of these should improve the discipline of medicinal chemistry and 
therefore drug hunting. This is a particularly pressing need, as a decade of corporate reorganization 
and consolidation has moved much medicinal chemistry into contract research organizations and 
off-shored suppliers without access to the historic corporate knowledge of large Pharma. Contract 
research organizations are constrained in the use of their clients’ data, so that knowledge mining 
across multiple projects is essentially impossible within these companies. 
Human aspects 
Discussions of technology often avoid the critical discussion that all methods are mediated through 
people. As in most professions, the key value of the human element in medicinal chemistry is to 
make the critical assessment of what situation a discovery project is currently in, and then to choose 
an appropriate strategy to respond with. Line and project managers therefore have to be aware 
that chemists are often making these critical decisions in the context of poor data with immature 
theory and their role is to support and challenge them appropriately.  All parties need to take 
responsibility to be on guard against the broad range of natural cognitive biases particularly the in-
group behaviors that can be expressed when working under pressure and this is where a more data 
driven approach can assist.  Across many fields, where an area is poorly quantified and tacit 
knowledge and experience are key, the Highest Paid Person's Opinion (HiPPO) may hold sway; this 
can obviously influence the uptake of new methods[15]. Some medicinal chemists may see a large 
knowledge base of potential solutions as a threat to their professional practice, and this may be the 
case if they only have a limited repertoire of tactics – or as a biologist colleague once described it 
"the chemists make the same compounds whatever the project". We must acknowledge that part 
of the development of professional medicinal chemistry is acceptance at a personal level that 
moving to more evidence led practice can be uncomfortable if it challenges our professional 
standing.  However we can choose to treat evidence led practice as a framework to develop our 
expertise as a medicinal chemist[16]. Finally, the learning from other disciplines is that increased 
access to automated knowledge enables an "augmentation strategy" where the person + machine 
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combination is more effective than either on their own[17]. These are described in the artificial 
intelligence literature as "centaur teams", with the possibility being held out that partnership 
between human and machine should allow the speed, thoroughness and lack of bias of machines 
to be complimented by the creativity, intuition and situational awareness of the human.  
 In the absence of an instruction manual of medicinal chemistry, which would describe how to 
change the structure of a compound to transform it into a drug, the practitioner must adhere to 
broad “rules” and theoretical principles. These necessitate playing safe and although no 
“transgressions against medicinal chemistry rules” might be made such as "never make an aniline" 
[18], by avoid challenging assumptions, they may also result in avoiding innovative solutions[19]. In 
an alternative extreme strategy, the practitioner may choose to believe in the “exceptionalism of 
the drug”, the “special” molecule that balances the conflicting properties; once this can be found, 
all will be well. The latter is a case of optimism bias, which can lead to an obsessive exploration of 
the end of a cul-de-sac when the overall picture may have been clear for some time. Under these 
circumstances, the argument may be made that “if only we find just the right compound it will be 
worth it when it gets to market”. Although true, the continued expenditure at the most expensive 
part of the drug discovery process, may represent a severe opportunity cost in that there may well 
be better series or projects to work on. 
 Within different organizations the process of capturing medicinal chemistry knowledge varies 
depending on an organization’s history, local culture and needs. Historically, the core process was 
essentially a scientific "apprenticeship" with experiential learning supported by older colleagues.  
The introduction of "wikis" – user maintained encyclopedias and storyboards of drug hunting 
projects has been discussed by others[20–22]. The offshoring and consolidation of medicinal 
chemistry has led to the move of significant numbers of experienced drug hunting medicinal 
chemists into universities. This clearly undermines the industrial "apprenticeship" approach. In both 
Europe and the United States the concern that medicinal chemistry education in industry is in 
trouble has been voiced with a view that industry-academia partnerships may present a 
solution[23–25]. This has enabled a more applied approach to the field being taught in universities 
but at the risk that those teaching are no longer practitioners and that the tools at their disposal are 
behind the current state of the art. Both of these approaches will still deliver a biased transfer of 
medicinal chemistry knowledge.   
Approaches to the systematization of medicinal chemistry 
If we seek the best guidance possible, we must develop a means to systematize medicinal 
chemistry knowledge. As for many disciplines, there are three main approaches to this: 1) case 
series - gathering together stories to identify common themes in success and failure, 2) a 
reductionist approach - attempting to define the underlying factors for compound efficacy, 
metabolism and toxicity, and 3) data mining and supervised learning/AI - identifying tactics which 
have a statistically robust evidence base. The requirement to gain intellectual property makes the 
sharing of compound data and structures (required for all three approaches) difficult as weak 
compounds within its scope may undermine a patent, and compounds outside a patent scope 
may represent an opportunity for others to exploit.  Although any of the approaches could be 
adopted either within private companies or on the censored public data, the broadest and most 
robust learning would be derived from access across both public and private data sets. 
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Figure 1 Hierarchy of evidence for medicinal chemistry tactics 
 In medicine, there is an acknowledged “hierarchy of evidence”[7] whereby case studies are 
seen as valuable in rapidly alerting practitioners to potential emergent issues such as safety issues 
and in generating hypotheses to test either mechanistically, via retrospective studies or randomized 
controlled trials. Retrospective studies in medicine carry more weight, with mechanistic studies and 
finally meta-analyses give most support for decision making. In the same way, it is possible to 
structure future attempts at better systematizing medicinal chemistry with a broad base of case 
studies feeding into both experimental and retrospective analyses to collate evidence to support a 
hypothesis and explore. A mechanistic chain can then be developed from evidence to hypothesis 
[26]. 
Case Studies and Series in Medicinal Chemistry 
The majority of medicinal chemistry teaching has been based around case studies of individual 
drug discovery stories[27–29]. Though educational, these run the risk common to anecdotes that the 
specific case is extrapolated and believed to be generally applicable. Time and effort can be 
wasted following an approach that only worked once - an example of the “base rate fallacy”[30]. 
Recently a number of publications have gathered together data in a more thematic approach, 
looking at particular functional groups and their effects[31–33]. These provide a more reliable view 
than overemphasis of particular solutions such as “fluorine blocks metabolism” [34] and that 
tetrazole is a general replacement for an acid [28]. However they still suffer the intrinsic limit of case 
study approaches in being vulnerable to the quality of the reviewers’ literature searching and the 
limits on published data. The emerging challenge to the case study approach is that as the size of 
the literature for review grows exponentially larger, curating case studies in a comprehensive and 
unbiased way will inevitably become increasingly untenable. 
 
Can Medicinal Chemistry be codified without sharing IP-sensitive structures? 
Part of the challenge in medicinal chemistry is in describing exactly what is done. There is a conflict 
here between the physics model of molecules as collections of sub-atomic particles and the 
structural representations used as shorthand by synthetic organic chemists. One challenge for 
practicing medicinal chemists is that although certain properties may appear continuous, it is hard 
to change them precisely when the tools to modulate properties are adding and removing atoms. 
More prosaically: finding an atom with half the volume of a chlorine but the same electronic 
properties may not be feasible.  Relating a desired change in biological properties to a 
corresponding change in structure is therefore more useful than relating it to a change in an 
alternative property such a lipohilicity. This requires a language for the description of changes in 
chemical structure to be developed. 
For instance, “add a fluorine para to the substituent on a monosubstituted phenyl ring” is a clear, 
actionable instruction to a medicinal chemist. It can also be transformed into a query to identify all 
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previous examples of such a change to be identified. This is a first step in moving to an evidence 
based approach in medicinal chemistry.  
 
Level Description Comments 
0 C-HC- electron withdrawing group Carbon could be aromatic or 
aliphatic and a specific definition 
of "electron withdrawing group" is 
required. 
1 Ar-HAr-electron withdrawing group Ar = heteroaromatic rings of any 
size or composition, further 
substation allowed and not 
constrained 
2 Ar-HAr-Halo Halo defined as F,Cl,Br, I. 
3 Ar-HAr-F Only Ar is now variable 
4 Ph-HPh-F Specific to Ar = phenyl 
5 R-p-phenyl-H  R-p-phenyl-F Specific to substitution pattern on 
phenyl 
6 Whole-molecule-p-phenyl- H  
Whole-molecule-p-phenyl-F  
Single pair of compounds, an 
anecdote 
 
Table 1 Describing structural changes with increasing levels of detail 
Although the example described is a simple replacement of a substituent, the structural change 
could equally be a cyclisation, the shielding of a hydrogen bond acceptor by a vicinal methyl or 
the exchange of linking chains or core ring systems for isosteres. It is important to be sure that the 
structural change has been described and encoded in an appropriate fashion. The objective is to 
codify knowledge in a specific way so that the aggregated set of examples reveals a signal above 
the noise. For example, differing levels of specificity are shown in Table 1. Level 1 is the level at 
which a medicinal chemistry textbook might describe an approach, operating from the theoretical 
argument that because the predominant route of metabolism in aromatic rings is oxidative, 
destabilizing an incipient cation will reduce the rate of oxidation. As the transformation becomes 
more structurally specific, the number of examples will decrease and the variance of the effect will 
become smaller, indicating that the representation is capturing some correct feature of the 
chemical structure that influences the metabolic process. There is some evidence that aggregation 
at level 2 may offer some benefits as "fuzzy matched pairs"[35]. As soon as the transformations are 
aggregated, the details of the method of aggregation become an issue.  For example, if we were 
to group "aryl-hydrogen bond acceptor" as a component, the definition of what constitutes a 
hydrogen bond acceptor becomes important; the case of methoxy being a good acceptor on an 
aliphatic ring but poor on an aromatic ring is a simple example. At the other extreme, if just a single 
pair of compounds is specified, it completely describes the transformation, but is just a scientific 
anecdote. In the development of matched molecular pair methodology, two critical papers 
suggest that the level 3, Ar-HAr-F can be too unspecific and give a "smear" of outcomes, whereas 
the inclusion of more chemical context (equivalent to level 5 R-p-phenyl-H  R-p-phenyl-F) can 
give a result with a lower variance so increasing confidence that this could be a useful 
change[36][37].  The possibility of using context-encoded matched molecular pair analysis to share 
medicinal chemistry knowledge was proposed by Dossetter et al[38] in 2013, with a confirmation of 
the data security of such an approach provided by Swamidass[39] in 2014. 
Mining Unbiased Medicinal Chemistry Knowledge from Data 
The same root in physical chemistry that led to the study of model systems also drove the 
quantitative analysis of structure activity relationships (QSAR). The hope for broad scale models has 
been challenged by the shear size of accessible medicinal chemistry space[40]. Over the last two 
decades, three themes have been clear: the development of large scale QSAR models, the 
attempt to extract “simple rule models” for complex properties and the development of matched 
molecular pair analysis (MMPA) to analyze success frequencies for biological or physical 
properties[41]. 
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 Large-scale QSAR models have been developed mainly within Pharma as the only 
organizations with enough data to make adequately precise predictions. Their influence on 
broader practice has been limited by the constraint that it has been impossible to share the 
underlying structures between organizations or publicly. Even compounds anonymized by an 
identifier and the descriptors or fingerprints cannot be shared due to the information content in the 
descriptors presenting the opportunity to infer the probable structures[39]. The nature of the 
descriptors and the statistical approaches used also makes interpreting the models without access 
to the underlying structures difficult.  
 The "first wave" of simpler models were based on attempting to draw constraints around what 
may be “acceptable” chemical space and developed from the early and highly influential efforts 
of Lipinski [42]. Clearly the impact of poor solubility and permeability will have a negative effect 
throughout the drug discovery process from the validation of hits in cellular assays to in vivo studies.  
Further elaboration of the drug-likeness approach has been described by Congreve[43], 
Lovering[44] and Gleeson[45] and the PAINS style filters[46]. Recently, these have been critiqued for 
their methodology and more particularly for the underlying belief that  “Given that drug discovery 
would appear to be anything but simple, the simplicity of a drug-likeness model could actually be 
taken as evidence for its irrelevance to drug discovery.”[47,48]. It is not that focusing on simple 
molecular weight, logP hydrogen bond donor and acceptor counts is wrong, it is just usually not 
sufficient to solve medicinal chemistry problems. 
 In the early years of the 21st century, the formalization of matched molecular pair analysis 
(MMPA) was developed[1,49]. This is an approach that medicinal chemists had been using 
informally and with a rich statistical heritage in analogous medical matched cohort studies. The 
evolution of this approach was driven by its apparent simplicity and clarity of interpretation.  A 
number of large scale MMPA have been carried out for a range of physical and biological 
endpoints[38]. A variety of methods have been developed to automate the MMPA process. One 
difference between MMPA and QSAR that is often overlooked is that QSAR generates declarative 
knowledge – a QSAR model is presented with a molecule and it makes an estimate for the 
modeled property. MMPA creates procedural knowledge – “if you change this 
substituent/linker/scaffold to the suggested group it will give a certain change in the property”.  
MMPA presents new molecules to chemists as potential solutions.  
 In the last four years an approach has been tested to address the goal of sharing medicinal 
chemistry knowledge operating within the IP constraints around sharing primary structural data.  It 
was recognized that matched pair relationships could be used as a “one way mapping” or 
“trapdoor” function. Once compounds have been assigned as members of a pair by a 
transformation, the original structures can no longer be inferred from the transformation.  This has 
allowed aggregation of data across three large Pharma and consequently testing the question of 
whether particular medicinal chemistry methods are general or specific within a chemical class or 
project context. This addresses the critique that like QSAR models, the inferences depend on the 
data sets. Previously, either the results have been drawn from individual large Pharma datasets, 
where the risk is that particular individual projects or chemical series are generating an inference 
particular to that series, or from published data with the concomitant severe sample selection 
biases and small compound sets for some critically important biological endpoints. 
 The different approaches to automatic detection of matched molecular pairs have been 
reviewed[50]. Three critical features of a method for the capture of medicinal chemistry knowledge 
are: the ability of an algorithm to capture as many of the matched pairs a medicinal chemist would 
identify as possible, avoiding inclusion of "false pairs" and the transparent encoding of chemical 
environment as described above. A detailed analysis of the synergy between two complementary 
methods, "Fragment and Index" and "Multiple Common Sub Structure" (MCSS) has recently been 
published[51] showing on average a third of the pairs are found exclusively by one or other 
method, and a third are found by both.   
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Figure 2 Mean percent of matched pairs found over 6 public data sets by method (VEGF, Dopamine 
transporter, GABA-A receptor, human D2 receptor, acetylcholine esterase, monoamine oxidase) 
Examples of Medicinal chemistry Knowledge gained by sharing MMPA analysis: 
In the database created by merging medicinal chemistry knowledge from AstraZeneca, 
Genentech and Roche, a huge number of statistically significant medicinal chemistry rules were 
extracted as summarized in Table 2.  
 
Datasets(s) Number of increase / decrease/ 
neutral rules 
logD7.4 153,449 
Solubility 46,655 
In vitro microsomal clearance: 
human, rat ,mouse, cyno, dog 
88,423 
In vitro hepatocyte clearance : 
human, rat, mouse, cynomolgus monkey, dog 
26,627 
MDCK permeability A-B / B–A efflux 1,852 
Cytochrome P450 inhibition: 
2C9, 2D6 , 3A4 , 2C19 , 1A2 
40,605 
Cardiac ion channels 
NaV 1.5 , hERG ion channel inhibition 
15,636 
Glutathione Stability 116 
Plasma protein binding 
human, rat ,mouse, cynomolgus monkey, dog 
64,622 
Table 2 Number of Statistically significant rules found from merging AstraZeneca, Genentech and Roche 
in vitro ADMET knowledge 
Definition of a rule: 
 
There are several challenges in creating a definition for what constitutes a "rule". 
These are: managing out of range data, the contrast between the amount of evidence 
and the strength of the signal, avoiding the assumption that the data is normally 
distributed, and a metric simple enough to explain quickly to a non specialist. We therefore 
use a simple "coin flipping model" [51]. A given matched pair will either show an increase 
or a decrease in the measured property (where both members of a pair are out of range, 
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that pair is excluded). The number of increases and decreases are then treated as the 
equivalent of "heads" and "tails" in a binomial test. The results are tested to see if the 
distribution of increases and decreases would be outside what would be expected for a 
random distribution 95% of the time. Using this method, the more evidence (number of 
examples) that a rule has, the lower the frequency of a given direction is needed for it to 
pass statistical significance.  Four worked examples show some effects of this:   
32 matched pair examples of a rule are found: 23  (72%) lead to an increase this just passes 
the binomial test at 95% confidence with a p-value of 0.02; 
16 matched pair examples: 13 lead to an increase just passing the binomial test with a p-
value of 0.02, but now 81% of the examples need to increase to pass significance; 
8 matched pair examples: now all 8/8 examples must increase reporting a p-value of 0.007, 
however if only 7/8 examples show an increase the p-value is 0.07, so there is a 7% chance 
that this distribution could be seen from a random distribution of examples; 
5 matched pair examples: 5/5 show an increase in the property – this fails the binomial test 
with a p-value of 0.06, therefore even if 5 examples all show an increase from this rule, 
there is a 6% chance this could be due to a random distribution.  Only where there are 6 or 
more examples of a matched pair can the binomial test be passed. This is an important 
piece of learning for "anecdotal" medicinal chemistry discussions, unless there are 6 or 
more examples, using a simple binomial test, it is not possible to state with >95% confidence 
that the medicinal chemistry "rule" proposed is anything other than a random distribution. 
 
The large amount of unique knowledge found as shown in the filled donut diagram  (Figure 2) 
mirrored the expected lack of overlap between different Pharmaceutical company collections[52]. 
 
 
 
 
Figure 3 Origin of rules by company. The overlaps indicate the rules that contain examples from multiple 
companies, i.e. 58,000 rules had examples from all three companies, 139,000 rules were derived from 
company A data only. The total gain in rules by company was A:62%, B:156%, C:118%. 
 On inspecting this cross company database, one noticeable feature is the fine structural 
detail now available to direct medicinal chemistry. For example, previously the understanding of 
the probability of success of using a fluorine as a metabolic block could be summarized as 
“sometimes it works, sometimes it doesn’t” with a number of case studies available[32]. Given the 
frustration and waste when a hard to make or expensive building block fails to deliver the reduction 
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in metabolism hoped for, knowing the circumstances where a "fluorine block" is likely to work is a 
significant benefit. 
 
Figure 4 HF substitution effects on human microsomal clearance in different environments and extreme 
examples 
If the effect of HF is split for different chemical environments around the point of change (Figure 
4), the historical distribution of successful transformations can be seen. The summary of this is that for 
the vast majority of chemical environments, the H F transformation has made less than 2 fold 
difference in either direction in human microsomal clearance (-0.3 < log(Mic Clint) < 0.3). There 
are, however, precise situations where the H F transformation has been a good strategy, a 2 fold 
or more increase in metabolic stability would be expected (log(Mic Clint) <= -0.3), and similarly in a 
few precise environments, a HF transformation has significantly increased the rate of metabolism 
(log(Mic Clint) >= +0.3). Two of these extreme examples are shown in Figure 4. 
 
As recognized by Hussein and Rea[53], the vast majority of transformations have very few example 
pairs supporting them and overall form a Zipfian distribution. This is an unsurprising consequence of 
the vast size of chemical space. The effect of this is that in merging data between companies, for 
the very few, very commonly observed transformations little new information is gained, however for 
the vast majority of transformations there is the opportunity to learn more by pooling examples. For 
the human liver microsome set as shown Figure 5, 99% of the transformations in the data set had 
been observed less than 6 times (the minimum criteria for statistical testing). All of which represent 
an opportunity for increasing knowledge by pooling data. 
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Figure 5 Distribution of number of pairs per transformation for a single company"s human microsomal 
clearance data 
 
In looking at the knowledge in the database, further questions can immediately be addressed:  Which medicinal chemistry changes are highly reproducible?  What should I usually expect for a given structural change?  What is the range I expect for that change (and therefore when to be suspicious?)  How do they relate to “theory” and “experience” 
 
 One example of this is in looking at the relationships between properties for the same 
chemical transformation. For example (Figure 6) when the large number of transformations for 
which there is both measured logD and measured solubility data is examined, a familiar broad 
trend is clear. As experience and theory suggest, overall solubility is negatively correlated with logD, 
as logD increases, solubility decreases – however several more inferences are possible from this 
data. First: overall a drop of 1 unit logD gave, on average, a increase in solubility of approximately 
0.6 log units (4 fold), second – the "lipophilic efficiency" of different transformations has a huge 
range.  For example for isolipophilic changes (median logD = 0), the effect on median solubility 
could range from -1.5 to +1.5, a 30 fold change in either direction. The colouring of regions of the solubility/logD transformation plot shows that the majority of transformations that increase 
solubility are inefficient for the amount of solubility gained with respect to change in logD – ie solubility < -   where solubility >0.  There are a small number of transformations that are 
unexpectedly good as outliers where logD can be increased and solubility increases as well, these 
represent very high value transformations to medicinal chemists. 
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Figure 6 Solubility vs logD effects, >=20 examples per rule, n=13453. R2 = 0.66, slope = -0.57, intercept = 0. 
Magenta line: line of slope -1, intercept 0, dark blue line linear best fit, pale blue density ellipse contains 
99% and the mid blue ellipse contains 50% of the transformations. 
A very similar picture is seen when we look at the relationship between metabolic stability and 
logD. The same form of analysis holds true for the other in vitro endpoints studied and 
interesting outliers have been identified [54].  
 
 
Figure 7 Human microsomal clearance vs logD, >=20 examples per rule, n=11,572. R2 = 0.40, slope 0.23, 
intercept = 0. Magenta line: line of slope 1, intercept 0, dark blue line linear best fit, pale blue density 
ellipse contains 99% and the mid blue ellipse contains 50% of the transformations. 
 
 Beyond analysis of the efficiency of medicinal chemistry transformations with respect to 
lipophilicity, other SAR insights can be gained. Comparing the effects of sets of transformations on 
different ion channels can be important; a transformation that reduces hERG binding but increases 
NaV1.5 ion channel binding would be a pyrrhic victory.  Similarly, how the same transformations 
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have different effects on hepatic metabolism according to species can help to avoid moving 
compounds forward that will have a beneficial effect on rodent metabolism but a poorer effect on 
human or dog.  These insights have the potential to make very considerable savings in the 
progression of compounds in late lead optimization. 
Potential Risks of collating Medicinal Chemistry Knowledge 
 
One risk that has been voiced in generating a large knowledge base is that "everyone will just do 
the same thing" in particular that it could lead to limiting medicinal chemistry to what has been well 
explored in the past.  There are several responses to this. The first is to acknowledge that actually 
given the evidence of multiple published analyses[55,56] and above (Figure 5 Distribution of 
number of pairs per transformation for a single company"s human microsomal clearance data) this 
is where medicinal chemistry is currently.  The evidence is that medicinal chemists apply a limited 
set of tactics very frequently. Understanding the historic success rates for these at least allows the 
best of the "common tactics" to be tried first. With a broader collection of medicinal chemistry 
knowledge the chemist may be prompted to explore outside their preferred set of tactics and 
exploit the learning of others more effectively.  Chemists may also then take on the higher level 
analysis grouping successful solutions into classes and generating more strategic hypotheses which 
then can be used to create new solutions to test. 
Medicinal Chemistry Knowledge Exploitation 
A database of validated medicinal chemistry transformations can be exploited in a number of 
ways. The most obvious is as a searchable resource to suggest alternatives and to benchmark 
proposed ideas. There are additional benefits in encoding the transformations as reactions in that 
enumeration software can be used to convert “problem” molecules into potential solutions.  This 
was originally recognized by Fujita with the development of EMIL[57] and then again in Abbott’s 
Drug Guru software[58] where manually encoded reactions were used to capture medicinal 
chemistry experience. Extension of this type of approach via cyclic enumeration and scoring can 
create "evolutionary optimization"[59],[60]. Integration of a knowledge base of transformations with 
an enumerator creates an expert system that can propose solutions to medicinal chemistry 
problems – one class of artificial intelligence. 
 Automated encoding of transformations between molecules also enables further possibilities 
such as using a set of known measured molecules to predict the properties of a proposed new 
molecule by matching the transformations from the known to the proposed generating a de facto 
“ratings” service. Further possibilities include a broader scale exploration of the matched series 
concept[61–63]. Here, a set of compounds with a common core but a range of different 
substituents generates an SAR "fingerprint". Biological targets demonstrating the same SAR can be 
aligned and useful questions like "given that the SARs of these two series align; what is the potency 
of this new substituent likely to be?", ""what is the most potent substituent that can be transferred 
from one aligned series to another?" and "what biological targets have the same SAR as my 
target?" Clearly this can address one of the other key weak points in the chemical arm of drug 
hunting: generating potent chemical leads. Even more generally, the network of transformations 
can be explored to see if knowledge can be inferred: if AB and B C can A C be estimated or 
will errors propagate too strongly? Alternatively if AB, AC, AD all lead to a decrease in toxicity, 
can A be designated a toxophore? 
What role for artificial intelligence to improve Medicinal Chemistry 
The last decade has seen a resurgence in artificial intelligence (AI). In its current form, the 
predominant AI paradigm is the analysis of very large data sets with statistical machine learning 
methods. The most ubiquitous uses have been in image recognition and natural language 
processing of textual data. These have developed from experimental identification of cat pictures 
and film review classification to ubiquitous face recognition and sentiment analysis in marketing. 
[64,65] This has been enabled by three factors: massive free training data sets harvested from the 
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internet, hardware acceleration driven by the gaming industry and these two factors in turn 
enabling the application of complex neural net architectures such as deep, convoluted and 
adversarial networks. The application of these methods in drug hunting has been demonstrated in 
high profile cases such as the Merck Kaggle challenge[66], the NIH Tox21 challenge[67] and the use 
of generative neural networks to identify novel RXR agonists[68]. More recent successes in the test 
arena of game playing, Alpha Go[69] and Alpha Go Zero[70] have demonstrated that extending 
neural net methodologies continues to create new opportunities. The potential to integrate AI 
systems with automated synthesis and testing synthesis "closing the loop" of cyclic prototyping has 
recently been reviewed[71] . This would have the potential of replacing the medicinal chemist, 
however as we discuss below, the machine learning methods and critically, data sets they are built 
on will have to significantly improve before "self-driving drug hunting" becomes a reality. Currently, 
AI appears to be at the peak of its latest hype cycle with the "Trough of Disillusionment" beckoning, 
hopefully this will  followed by more realistic integration into drug hunting and the "Plateau of 
Productivity".[72] 
 One simple question however is, will the current class of AI approaches be able to address the 
complex multi parameter optimization problem of drug discovery? A trite summary of the neural net 
based systems appears to be that "neural nets are good at tasks humans are good at". Asking the 
question: "what tasks in drug design are humans good at?" does not bode well for AI's based on this 
technology.  Indeed, multi-objective design remains an intrinsically hard problem because as the 
number of objectives rises the training data becomes increasingly sparse; this is the "curse of 
dimensionality". A further critical issue not often explicitly addressed is that the non-chemical 
successes in AI have been built on vastly larger training data sets than currently available within any 
given Pharma or publicly for drug hunting.  Machine learning approaches built on data sets that are 
too small tend to be "brittle": they appear reasonable until challenged with situations where they 
are undertrained at which point the predictions become poor. The "human backstop" in a human-
AI mixed team should mitigate this risk. Lack of interpretability is a further challenge in the 
application of neural net based and other "black box" machine learning algorithms. Unlike 
regression-based machine learning it's very hard to expose which factors (in chemical terms, which 
substructures) are driving the estimate the algorithm is generating. At a human level this 
disempowers the user as they are faced with "doing what the machine says" or not, but without a 
method to assess the validity of the prediction.  This may decelerate adoption of AI methods in the 
scientific arena.  Auditable AI is of such significant interest as to have been recognized by the US 
National Science and Technology Council as a key component to building trust in AI systems in their 
2016 R&D Strategic Plan.[73] At a technical level, the algorithm may be making a prediction on a 
very small subset of the data, or may have effectively encoded biases in the data. This algorithmic 
bias is an area of significant current concern and research [74]. Without being able to understand 
the drivers of predictions, the medicinal chemist may be just perpetuating existing organizational 
preferences but with the "fig leaf" of computational support.  Interpretability is a harder area to 
research than predictive accuracy since it requires a subjective assessment rather than a numerical 
score.  One can imagine uncritical overreliance on AI methods exposing drug hunting teams to 
significant risks. Without experienced medicinal chemists to audit the rationale behind suggestions, 
black box models operating outside their domain of applicability could be making wild suggestions 
and a project could waste significant resource in making unlikely compounds. This is particularly 
relevant as novel biological target classes are explored, where although chemists may not have 
specific knowledge of an area, they have the skills to construct sets of experiments to explore the 
parameters of the medicinal chemistry search space.  
 The success of AI and machine learning approaches in medicinal chemistry is critically 
dependent on access to large enough data sets to train on and methods that enable interrogation 
and interpretation. It seems most likely though, that to misquote McAfee and Brynjolfsson: "AI won’t 
replace medicinal chemists, but medicinal chemists who use AI will replace those who don’t".[75] 
 
Artificial Intelligence and Chemistry 
 
Artificial intelligence has addressed chemical problems throughout its history. .  
The  "expert system" era which used rules encoded by specialists produced DENDRAL [76] 
which could identify compounds from their mass spectra, CASE [77] and DEREK [78] for 
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identifying potential toxicities, EROS [79] and LHASA [80] the systems for proposing synthetic 
routes. All these were based on human experts encoding a set of "rules" in a format that could 
be used computationally to rank potential solutions.  As discussed above, the more modern 
"Big Data" approach is to use large data sets and statistical methods to infer either rules, or 
statistical algorithms (such as the variety of neural net architectures) that when presented with 
a problem will provide the most likely solution(s). The question "is this intelligence in chemistry?" 
can be addressed by a Feigenbaum test [81]: if you present a system with a chemistry based 
challenge and the response is indistinguishable from that which a trained chemist or group of 
chemists would provide, then it's indistinguishable from intelligence. 
 
Medicinal Chemistry Knowledge in the Drug Discovery Ecosystem 
As discussed at the start of this article, medicinal chemistry is an applied science. The majority of 
therapeutic agents have been discovered in the private sector and in the vast majority of cases 
developed there.  Drug discovery and development is highly regulated and expensive so 
organizations that carry this out need large capital reserves to develop and market new agents. 
Therefore the sharing of knowledge of how to discover and develop drugs better has an implicit 
tension. For a large Pharma, which has invested significantly in large scale compound synthesis and 
testing to generate data, the value of sharing knowledge with an equivalent sized organization is 
relatively straightforward to assess.  Both parties are expecting an approximately equal benefit. This 
can be described as a transactional relationship, although each party may not be able to estimate 
the exact return on investment, there is the assumption that for each party the knowledge will be 
equally useful. The value that can be extracted from the new knowledge gained depends on the 
efficiency with which research is undertaken in each organization. 
 Taking a more strategic view: Pharma could improve the quality of in-licensing candidates by 
sharing knowledge more widely with the academic, not-for-profit and biotech sectors. This would 
result in faster drug discovery in the non-large Pharma sector and hence cheaper and better in-
licensing candidates which in turn gives a better long term return on investment. However, this "rising 
tide lifts all boats" argument is harder to quantify as the benefits are more distant, and therefore it is 
more difficult for Pharma managers to make the case that it is valid.  This is an example of the 
cognitive bias of hyperbolic discounting – longer term, larger rewards being underestimated. A 
short term counter argument for internal Pharma research teams is that generating more external 
competition to their endeavors is a counterproductive to their own survival.   
 Within Pharma discovery teams, the argument is put forward that SAR knowledge represents 
key intellectual capital for their company. This appears to be rarely supported in practice as large 
Pharma frequently relocate research centres or outsource programmes which inevitably leads to 
loss of tacit knowledge. Within the not-for-profit sector it is proposed that "open source drug 
discovery" is analogous to "open source software". Though there are parallels in that both fields are 
involved in generation of intellectual property, there are very significant differences in the 
regulatory regimes for software and pharmaceuticals, consequences of errors and the product life 
cycles. Counterbalanced against this argument is the widely held visceral public view that drug 
discovery is a "public good", which leads to the Pharma sector demonstrating "corporate social 
responsibility" (CSR) in funding neglected disease research and providing low cost critical medicines 
to poorer parts of the world in for example in the treatment of HIV and parasitic worm infections. It is 
reasonable to expect that, as in the case of CSR, different companies will take different views on 
the strategic benefit of making their knowledge more widely available and then some may see this 
as another arena in which to compete for reputational gain. 
Conclusion 
From a technical perspective, a sufficiently large medicinal chemistry database of transformations 
may provide novel approaches to improving drug discovery. A record of historical successes can 
spur the development of novel solutions by combining old approaches or seeing a conceptual link 
between multiple previous successes. The question is asked perennially "what if in the end we all 
make the same compounds" which appears to ignore the evidence of the vast size of chemical 
 17 
space, it's huge diversity and its under exploration by chemists to date. Huge numbers of ring 
systems are unsynthesised and the current exploration of macrocyclic molecules [82] towards 
creating synthetic natural-product-like structures extends the reach of medicinal chemistry space 
still further. Yet more knowledge is undoubtedly there for the elucidating, but it will only become 
clear when we have sufficient data. 
 Conceptually, the use of a sufficiently large corpus of knowledge may be considered 
analogous to the effect that massive datasets have in automated language translation, where 
above a certain threshold, prediction becomes highly effective[83]. Treatment of emerging 
pathogens and the diseases of an aging population may require new chemistries and the exploring 
of multiple biological targets. To bring these "within range" of the investment available needs the 
application of all the knowledge we have. Enhancing our medicinal chemistry knowledge seems a 
central component in this task. The value of a very large scale systematized medicinal chemistry 
knowledge base appears to be hard to dispute. The technical and legal challenges have been 
overcome. However, the strategies for sharing such knowledge are corporate issues to be 
addressed by the leaders in our industry.  
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